Assessment of azithromycin as an anticancer agent for treatment of imatinib sensitive and resistant CML cells. Ozkan T, Hekmatshoar Y, Karabay AZ, Koc A, et al. Leuk Res 2021;102:106523.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Ozkan T, Hekmatshoar Y, Karabay AZ, Koc A, et al. Assessment of azithromycin as an anticancer agent for treatment of imatinib sensitive and resistant CML cells. Leuk Res 2021;102:106523.
PMID: 33607534